Amgen’s UPLIZNA approved in EU as first CD19 myasthenia gravis therapy, biannual dosing

Amgen wins EU approval for first CD19 therapy in myasthenia gravis

First-in-class CD19 option offers biannual dosing and steroid-sparing promise

Amgen announces that the European Commission approves UPLIZNA (inebilizumab) as an adjunct to standard therapy for adults with generalized myasthenia gravis (gMG) who are seropositive for acetylcholine receptor (AChR) or muscle‑specific kinase (MuSK) antibodies. The decision marks the first CD19‑directed therapy authorised in Europe for these patient groups and establishes a twice‑yearly maintenance dosing schedule following two initial loading doses, a regimen the company says delivers durable disease control and convenience for patients and clinicians.

The approval rests on data from the phase 3 Myasthenia Gravis Inebilizumab Trial (MINT), the largest biologic study to include both AChR‑ and MuSK‑positive patients and the first to implement a structured steroid‑reduction protocol. Under the trial’s tapering plan, patients begin steroid reduction in week 4 with a target prednisone dose of 5 mg/day by week 24; by week 26, 87.4% of patients receiving UPLIZNA and 84.6% receiving placebo have reduced steroid doses to 5 mg/day or less. Amgen highlights UPLIZNA’s selective targeting of CD19‑expressing B cells as addressing a core pathogenic mechanism in this B‑cell–dependent autoimmune disorder.

Clinicians and company officials say the new option may reduce reliance on long‑term steroids, which carry well‑known adverse effects, and improve quality of life for an estimated 56,000–123,000 people in Europe living with gMG. Amgen signals it will work with European health systems on reimbursement and timely access, while clinical experts note the twice‑yearly maintenance schedule could simplify chronic management and support longer‑term disease control.

Patient access and uptake remain near‑term priorities

Amgen indicates engagement with payers and national health authorities to secure reimbursement and rapid availability for eligible adult patients. Adoption will hinge on health‑system assessments of MINT’s efficacy and safety data versus existing standards of care, as well as real‑world demonstration of steroid reduction and durable benefit.

Sector pressures sharpen strategic focus across big pharma

The approval comes as European drugmakers face a looming patent cliff and intensifying attention on pipelines and M&A to offset revenue losses. Executives and analysts say 2026 is shaping up as a pivotal year for launches, pricing rules and strategic deals that will determine how companies translate regulatory wins into sustained growth.